The neurotoxic effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was tested on mice lacking the dopamine (DA) transporter (DAT-/-mice), Striatal tissue DA content and glial fibrillary acidic protein (GFAP) mRNA expression were assessed as markers of MPTP neurotoxicity. MPTP (30 mg/kg, s.c., b.i.d.) produced an 87% decrease in tissue DA levels and a 29-fold increase in the level of GFAP mRNA in the striatum of wild-type animals 48 h after administration. Conversely, there were no significant changes in either parameter in DAT-/-mice. Heterozygotes demonstrated partial sensitivity to MPTP administration as shown by an intermediate Value (48%) of tissue DA loss. Direct intrastriatal infusion of the active metabolite of MPTP, 1-methyl-4-phenylpyridinium (MPP+; 10 mM), via a microdialysis probe produced a massive efflux of DA in wild-type mice(>320-fold). in the DAT-/-mice the same treatment produced a much smaller increase in extracellular DA (sixfold), which is likely secondary to tissue damage due to the implantation of the dialysis probe. These observations show that the DAT is a mandatory component for expression of MPTP toxicity in vivo.
|Titolo:||Dopamine transporter is required for in vivo MPTP neurotoxicity: Evidence from mice lacking the transporter|
FUMAGALLI, FABIO (Secondo)
|Parole Chiave:||Dopamine transporter; Glial fibrillary acidic protein; Microdialysis; MPP+; MPTP neurotoxicity|
|Settore Scientifico Disciplinare:||Settore BIO/14 - Farmacologia|
|Data di pubblicazione:||1997|
|Appare nelle tipologie:||01 - Articolo su periodico|